Ductal carcinoma in situ of the breast treated with accelerated partial breast irradiation using balloon-based brachytherapy
Autor: | Angela B. Robbins, Philip Z. Israel, Frank A. Vicini, Maureen Lyden, Mark McLaughlin, Paulomi Shroff, Keri Grier |
---|---|
Rok vydání: | 2009 |
Předmět: |
Subset Analysis
Oncology Adult medicine.medical_specialty medicine.medical_treatment Brachytherapy Breast Neoplasms Balloon Whole Breast Irradiation Internal medicine medicine Humans skin and connective tissue diseases Aged Retrospective Studies Aged 80 and over Univariate analysis business.industry Partial Breast Irradiation Ductal carcinoma Middle Aged Catheter Carcinoma Intraductal Noninfiltrating Surgery Female Radiotherapy Adjuvant Radiology business |
Zdroj: | Annals of surgical oncology. 17(11) |
ISSN: | 1534-4681 |
Popis: | We reviewed our institution’s experience treating patients with ductal carcinoma in situ (DCIS) of the breast with balloon-based accelerated partial breast irradiation (APBI) to determine the efficacy of this treatment approach in this group of patients. A total of 126 cases of DCIS seen and treated with APBI using balloon-based brachytherapy constitute the study population. The median age at diagnosis was 59 years (range, 37–82) with 21% younger than age 50. Nuclear grade distribution was 52.5, 41.4, and 6.1% high, intermediate and low, respectively. Of these patients, 86% had estrogen receptor positive DCIS. The median tumor size was 6 mm (range, 1–26). Margins of excision were negative in 98.4% of patients. All patients were treated with 34 Gy in 10 fractions using either the MammoSite™ or Contura™ breast brachytherapy catheter. A total of 87 patients (73.1%) were placed on adjuvant tamoxifen or arimedex. With a median follow-up of 24 months (range, 0.7–73.9), three (2.4%) ipsilateral breast tumor recurrences (IBTRs) developed for a 2-year actuarial rate of 0.81%. Recurrences developed 4.8, 24.7, and 24.9 months after treatment. On univariate analysis, no variable was associated with IBTR. A subset analysis of the first 50 consecutive patients treated was also performed. With a median follow-up of 40 months (range, 15.6–73.9), one IBTR developed for a 3-year actuarial rate of 2.15%. Early results in patients with DCIS treated with APBI using balloon-based brachytherapy produced results similar to those with invasive cancer treated with APBI or DCIS treated with whole breast irradiation. |
Databáze: | OpenAIRE |
Externí odkaz: |